Journal of Clinical Oncology
Articles in this Issue
Impact of a comprehensive multidisciplinary tumor board program on treatment decision-making and patient compliance in a tertiary care hospital in Thailand.
324 Background: Multidisciplinary Tumor Boards (MTBs) are integral to quality cancer care, promoting evidence-based treatm...
Subtype-specific cell-surface glycocalyx–associated molecular expression programs revealed by public single-cell RNA sequencing in breast cancer.
62 Background: The cell-surface glycocalyx (GCX) is a carbohydrate-rich layer covering epithelial cells and plays an impor...
Hepatic arterial infusion chemotherapy combined with transcatheter chemoembolization, camrelizumab, and apatinib for BCLC stage C hepatocellular carcinoma: A retrospective study.
295 Background: This study assessed the combination of hepatic arterial infusion chemotherapy (HAIC), transcathete...
Treatment timelines, care delivery gaps, and their impact on outcomes in postoperative radiotherapy for head and neck cancer.
229 Background: Delays in treatment have been associated with inferior outcomes in head and neck squamous cell carcinoma (...
Effect of curcumin on anti-tumor immune cell profiles in colorectal cancer patients receiving cytotoxic chemotherapy.
145 Background: The interaction between cancer cells and the immune system critically influences tumor progression and res...
H&E 3.0: An AI-driven, chemical-free virtual histology solution to enable worldwide multiomics profiling.
290 Background: Haematoxylin and eosin (H&E) staining is central to routine histopathological diagnosis, but limited a...
Sociodemographic disparities in pancreatic cancer incidence between 2000 and 2022: A Surveillance, Epidemiology and End Results analysis.
129 Background: Pancreatic ductal adenocarcinoma (PDAC) presents with significant morbidity and mortality. Five-year survi...
Tislelizumab combined with standard therapy for conversion treatment in patients with MSS, initially unresectable colorectal cancer liver metastases (CRLM): A prospective, phase II study.
TPS159 Background: The liver is the most common site of metastasis in colorectal cancer, and liver metastases represent th...
Neoadjuvant anti-PD-1 monotherapy in MSI-H locally advanced gastric cancer: 3-Year survival without surgery.
106 Background: Neoadjuvant immunotherapy (IO) with anti–PD-1 inhibitors has shown promise in microsatellite instability–h...
The impact of malnutrition on chemotherapy toxicity and quality of life in advanced breast cancer patients.
349 Background: Sarcopenia has not been recognized as a problem in breast cancer. There was still limited data whether sar...
Predictors of post-operative morbidity and mortality after debulking surgeries for gynecological malignancies.
220 Background: Gynecological malignancies, particularly ovarian and endometrial cancers, represent a major contributor to...
Liposomal irinotecan (HR070803) plus fluorouracil and bevacizumab as second-line treatment in advanced colorectal cancer: Cohort A results from a phase 2 trial.
100 Background: Irinotecan-based regimens are standard second-line therapy for advanced colorectal cancer (CRC). Liposomal...
Single-cell analysis and functional profiling to reveal Galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma.
245 Background: Histological transformation of follicular lymphoma (tFL) represents an aggressive subtype characte...
First-line maintenance olaparib in a low–body mass index Asian population with advanced ovarian cancer: Real-world outcomes from a Vietnamese cohort.
218 Background: Patients enrolled in pivotal poly(ADP-ribose) polymerase (PARP) inhibitor trials predominantly represent W...
Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.
211 Background: Currently, the established first-line therapy for patients with recurrent or metastatic CC is the platinum...
Efficacy of prophylactic dexamethasone in preventing opioid-induced nausea and vomiting in cancer patients: A randomized controlled trial.
313 Background: Opioid initiation for cancer pain is frequently complicated by nausea and vomiting, impairing adhe...
Multi-omics profiling of tumor DNA, mRNA, and plasma ctDNA in advanced lung cancer.
287 Background: The extensive landscape of therapeutic biomarkers in lung cancer has catalyzed the evolution of comprehens...
Detecting is living: Evaluation and promotion of oncological knowledge in medical students through the incorporation of exploration workshops, an initiative led by the Oncology Student Interest Group of the Benemérita Universidad Autónoma de Puebla endorsed by ASCO.
342 Background: In Mexico, cancer accounts for more than 190,000 new cases and 83,000 deaths annually. Therefore, it is cr...
Place of death patterns among patients with renal cell carcinoma in the United States: A 24-year nationwide analysis.
335 Background: Despite advances in targeted and immune-based therapies, renal cell carcinoma (RCC) remains associated wit...
Preoperative prediction of p53abn endometrial cancer molecular subtype using a T2-weighted MRI radiomics fusion model: A multi-center study.
204 Background: Endometrial cancer is a leading cause of cancer mortality in women worldwide. The Cancer Genome Atlas (TCG...
Unraveling the role of NLRP1-mediated inflammation in glioblastoma pathophysiology.
74 Background: Glioblastoma (GBM) is the most aggressive type of brain cancer with a median survival of less than 14 month...
Fibroblast growth factor receptor 3 (FGFR3) alterations and response to immune checkpoint inhibition in metastatic urothelial carcinoma: A systematic review and meta-analysis.
182 Background: Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of metastatic urothelial ca...
SPP1⁺ macrophage influence on differentiation of radioiodine-refractory thyroid cancer through secretion of FABP4.
239 Background: Radioiodine-refractory papillary thyroid carcinoma (RR-PTC) is a dedifferentiated subtype of thyroid cance...
Hepatic arterial infusion chemotherapy plus immune checkpoint inhibitors and lenvatinib for locally advanced biliary tract cancer: A single-arm, exploratory study.
108 Background: Immune checkpoint inhibitors (ICIs) plus gemcitabine and cisplatin (GemCis) have become a standard first-l...
Tri-specific immune checkpoint engineering: Clinical translation of HCB301 targeting SIRPα, PD-L1, and TGF.
TPS90 Background: Tumor immune escape arises from coordinated suppression across innate, adaptive, and stromal compartment...